MedTrace Logo

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

NCT01058083 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2012-04-19

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)

Conditions

Interventions

DRUG

BMS-770767

Active, Oral, 15 mg, Daily, 28 days

DRUG

BMS-770767

Active, Oral, 50 mg, Daily, 28 days

DRUG

BMS-770767

Active, Oral, 150 mg, Daily, 28 days

DRUG

BMS-770767

Active, Oral, 50 mg BID, Daily, 28 days

DRUG

Placebo

Placebo, Oral, 0 mg, daily, 28 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01058083 on ClinicalTrials.gov